Optina Diagnostics
Optina Diagnostics is a Montreal-based medical device company that combines an FDA 510(k)-cleared hyperspectral retinal camera with AI clinical decision analytics to support early detection and management of Age-Related Macular Degeneration, selling to ophthalmologists and retina specialists.
- Company typePrivate
- Founded2011
- HeadquartersSaint Laurent, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Optina Diagnostics does
Optina Diagnostics is a Montreal-based private medical device and diagnostics company developing AI-enabled hyperspectral retinal imaging technology for early detection and management of retinal disease, with a primary focus on Age-Related Macular Degeneration (AMD). Its core offering combines an FDA 510(k)-cleared hyperspectral camera, which captures retinal images in approximately one second, with AI-driven clinical decision analytics designed to detect early and intermediate stage retinal disease, identify patients at high risk of vision impairment, and monitor disease progression and therapeutic response. The company is also extending the platform toward a cerebral amyloid status test for Alzheimer's detection, supported by a grant from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator.
Optina sells its hardware-and-software platform through enterprise direct sales to eye care specialists, including ophthalmologists and retina specialists, primarily in the United States, Canada, and Europe, where it is expanding clinical study sites. The revenue model is hardware-centric, anchored on sales of the FDA-cleared camera system bundled with AI analytics software, though pricing is not publicly disclosed and operates on custom quotes. The company is venture capital-backed, having closed a CA$24.8 million Series A in October 2021 led by DigitalDx Ventures with participation from Boehringer Ingelheim Venture Fund, supplementing earlier seed and pre-seed rounds from Canadian and US investors.
The company operates in a large and growing addressable market: an estimated 300 million people are projected to experience moderate to severe vision loss from AMD by 2040, with annual direct healthcare costs of approximately US$100 billion in the US and US$343 billion globally. Optina is led by CEO David Lapointe and co-founder and CFO Chantal Miklosi, with a team in the 11-50 employee range, consistent with a clinical-stage medical device company still building toward scaled commercial deployment.
Optina Diagnostics firmographics
Firmographics- Name
- Optina Diagnostics
- Legal name
- Optina
- Website
- https://optinadx.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Optina Diagnostics is a Montreal-based medical device company that combines an FDA 510(k)-cleared hyperspectral retinal camera with AI clinical decision analytics to support early detection and management of Age-Related Macular Degeneration, selling to ophthalmologists and retina specialists.
- Ownership category
- akta.pro rank
Optina Diagnostics industry classification
Industry- Product category
- Ophthalmic Diagnostic Imaging Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)
- akta.pro secondary industry
- Retina & Vitreous Specialists (HLAKAKAE)
Keywords
Where Optina Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Saint Laurent
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Optina Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of FDA 510(k) cleared hyperspectral camera systems and associated AI-powered analytics software to eye care specialists and healthcare providers for clinical decision support in AMD diagnosis and management.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Optina Diagnostics product offering
Product offeringCore offering
Optina Diagnostics develops an FDA 510(k) cleared hyperspectral retinal camera combined with AI-driven clinical decision analytics to enable eye care specialists to detect, identify, monitor, and manage Age-Related Macular Degeneration (AMD) in early, intermediate, and late stages. The platform captures hyperspectral retinal images in approximately one second and uses AI algorithms to support faster diagnosis, identify high-risk patients before vision loss occurs, and monitor therapeutic effectiveness in at-risk patients.
Product overview
Optina Diagnostics offers a unified Clinical Decision Analytics Platform built around an FDA 510(k)-cleared hyperspectral camera integrated with AI capabilities. The platform enables eye specialists to detect, identify, monitor, and enable rapid diagnosis and management of Age-Related Macular Degeneration across early, intermediate, and late stages. The core offering combines hardware (hyperspectral camera) with AI-driven software analysis to support clinical decision-making.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Decision Analytics Platform AI-driven retinal imaging platform that supports faster and more effective diagnosis and management of patients with Age-Related Macular Degeneration through clinical decision support capabilities, enabling detection, identification, monitoring, and patient-centric care across early, intermediate, and late stages of retinal disease.
Quantifiable outcome
- ~1-second scan time for early and intermediate stage retinal disease detection
Companies that use Optina Diagnostics
Customer profileSegments1 record
Ideal customer profiles1 record
Optina Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature2 records
Optina Diagnostics partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Optina Diagnostics competitors and assessment
Company assessmentDirect peers
- Optos (Nikon): Developer of ultra-widefield retinal imaging devices (optomap) widely used in eye care practices for AMD and retinal disease screening. Directly competes for the same clinical workflow with hyperspectral/oct imaging alternatives.
- Heidelberg Engineering: Specialist in OCT, confocal laser ophthalmoscopy, and retinal imaging diagnostics used in AMD management. Closely comparable product portfolio and customer base of ophthalmologists and retina specialists.
- Centervue (iCare): Manufacturer of fundus cameras and OCT systems (Eidon, Maestro) used in retinal disease screening including AMD. Directly competes in the ophthalmic imaging device category targeted at optometrists and ophthalmologists.
Emerging players
- AEYE Health: AI-based retinal analysis platform for primary care and screening settings with FDA clearance for diabetic retinopathy. Comparable as a retinal AI diagnostics competitor targeting similar screening economics.
- Digital Diagnostics: AI diagnostics company with FDA-authorized autonomous diagnostic system (IDx-DR) for diabetic retinopathy. Comparable as an emerging AI retinal diagnostics vendor with regulatory clearance and enterprise clinical channel.
- RetiSpec: Canadian AI-retinal-imaging company developing non-invasive Alzheimer's detection from retinal biomarkers. Closely comparable to Optina's cerebral amyloid/Alzheimer's application using hyperspectral retinal imaging.
- Eyenuk: AI retinal imaging company with FDA-cleared EyeArt system for autonomous diabetic retinopathy detection. Comparable AI-on-retinal-imaging business model targeting clinical screening workflows.
Broad incumbents
- Carl Zeiss Meditec: Global leader in ophthalmic diagnostic and surgical devices, including OCT and fundus imaging systems. Directly comparable as an established retinal imaging incumbent competing for the same eye care specialist customers.
- Nidek: Japanese manufacturer of ophthalmic diagnostic equipment including retinal cameras and OCT systems. Sells into the same ophthalmology and optometry customer base with overlapping retinal imaging use cases.
- Topcon Healthcare: Major ophthalmic device manufacturer offering OCT, fundus cameras, and AI-enabled screening solutions (including Maestrocare and Harmony). Comparable as a full-portfolio retinal imaging and AI diagnostics vendor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Optina Diagnostics social profiles
Digital presenceOptina Diagnostics compliance and trust
Trust signalCompliance1 record
Optina Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Optina Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
Optina Diagnostics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Optina Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Optina Diagnostics
What does Optina Diagnostics do?
Optina Diagnostics develops an FDA 510(k) cleared hyperspectral retinal camera combined with AI-driven clinical decision analytics to enable eye care specialists to detect, identify, monitor, and manage Age-Related Macular Degeneration (AMD) in early, intermediate, and late stages. The platform captures hyperspectral retinal images in approximately one second and uses AI algorithms to support faster diagnosis, identify high-risk patients before vision loss occurs, and monitor therapeutic effectiveness in at-risk patients.
Is Optina Diagnostics a public or private company?
Optina Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Optina Diagnostics founded?
Optina Diagnostics was founded in 2011. It employs 11 to 50 people.
Where is Optina Diagnostics based?
Optina Diagnostics is headquartered in Saint Laurent, Canada, in the North America region.
How does Optina Diagnostics make money?
One revenue line is on record: medical Device Sales.
Who are Optina Diagnostics's main competitors?
Direct peers on record are Optos (Nikon), Heidelberg Engineering and Centervue (iCare). Emerging players are AEYE Health, Digital Diagnostics, RetiSpec and Eyenuk. Broad incumbents are Carl Zeiss Meditec, Nidek and Topcon Healthcare.
Does Optina Diagnostics have an API?
No public API is recorded for Optina Diagnostics.
What industry is Optina Diagnostics in?
Optina Diagnostics's product category is Ophthalmic Diagnostic Imaging Devices. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 339115 and its SIC code is 3827.